NATIONAL HARBOR, Md. -- A novel immunomodulatory therapy demonstrated antitumor activity across a broad range of heavily pretreated, immunotherapy-resistant tumors, including objective responses in advanced non-small cell lung cancer (NSCLC), a preliminary study showed. Treatment with the Siglec-15-targeted monoclonal antibody NC318 led to disease control (response and stable disease) in...

Next Oncology, launched a year ago in San Antonio, is moving its headquarters to the Christus Santa Rosa Hospital-Medical Center campus as the phase I cancer research organization advances plans for expansion in the U.S. and abroad. Next Oncology has signed an 11-year lease for nearly 20,000 square feet at...

Hundreds of cancer drugs are in the pipeline with the potential to save millions of lives, and make even more inroads into this dreaded disease. But may of the tests are stalled, due to a lack of people willing to participate in the clinical trials which are required before a...

A study by Texas A&M University suggests that we no longer use the phrase 'cancer survivor' to refer to former cancer patients, and prominent San Antonio oncologist Dr. Anthony Tolcher agrees, News Radio 1200 WOAI reports. "Many people, it seems, don't particularly like that term," said Dr. Tolcher, who is...

July is UV Awareness Month, making it a good time to remind you that one in five Americans will develop skin cancer at some point in their lives. Local doctors are now revealing the research they participated in that found a breakthrough treatment for melanoma. Read more on News 4...

ASCO and ASCO's Conquer Cancer Foundation are proud to recognize the winners of ASCO's Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform cancer care around...

On the heels of disclosing last week that the company had adopted a stockholder rights plan – otherwise known as a "poison pill" for protection against hostile takeovers – Durham’s Heat Biologics (Nasdaq: HTBX) and its subsidiary Pelican Therapeutics have recruited some new scientific expertise. Heat disclosed in a filing...

At a time of rapid advancements in cancer biology and innovation, researchers are facing mounting challenges in finding enough patients to recruit for clinical trials. Although this has been difficult for many years, current trends in oncology drug development may be making the problem more acute. The proliferation of targeted...